Optogenetic Control of Immunometabolic Flux in the Stellate Ganglion: A Precision Bioelectronic Framework for Pharmaco-Resistant Ventricular Arrhythmias

Ventricular arrhythmias resistant to conventional pharmacological therapy and catheter ablation remain the leading cause of sudden cardiac death globally, with approximately 4.5 million annual fatalities despite maximal medical management and implantable cardioverter- defibrillator therapy that delivers reactive high-energy shocks causing myocardial injury and psychological trauma without addressing the underlying neural drivers of electrical instability. The stellate ganglion represents the final common pathway for sympathetic input to the ventricular myocardium, integrating descending central autonomic signals with peripheral afferent feedback from the ischemic heart through immunometabolic mechanisms wherein resident macrophages and satellite glial cells detect damage-associated molecular patterns released from injured myocardium and respond by producing pro-inflammatory cytokines including interleukin-1 beta and tumor necrosis factor alpha that fundamentally reprogram neuronal metabolism from oxidative phosphorylation toward aerobic glycolysis, creating a 3.7- fold increase in lactate production and 58% reduction in mitochondrial oxygen consumption that precedes ventricular tachycardia onset by four to six hours in preclinical models.